Eikon Therapeutics targets $908 million valuation in US IPO
I'm PortAI, I can summarize articles.
Eikon Therapeutics is targeting a valuation of up to $908.2 million in its U.S. IPO, aiming to raise $317.7 million by offering 17.65 million shares priced between $16 and $18. The company plans to list on Nasdaq under the symbol "EIKN". This IPO follows a resurgence in biotech listings, with other companies like SpyGlass Pharma and AgomAb Therapeutics also filing for IPOs. The offering is underwritten by J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, and Mizuho.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments